Table 2.
Disease‐directed management and outcomes (n = 109)
| Management | n (%) |
|---|---|
| Non‐pharmacological management | |
| Exacerbation action plan | 71 (65.1) |
| Smoking cessation support for active smokers (n = 15) | 15 (100) |
| Current or past pulmonary rehabilitation | 95 (87.2) |
| Non‐pharmacological breathlessness management education† | 109 (100) |
| Respiratory physiotherapy | 39 (35.8) |
| Domiciliary oxygen therapy | 76 (70.3) |
| Pharmacological management | |
| LAMA inhaler(s) | 88 (80.7) |
| LABA + ICS inhaler(s) | 84 (77.1) |
| Up‐to‐date respiratory vaccines | 103 (94.5) |
| Referral for advanced therapies | |
| Endobronchial valve insertion | 6 (5.5) |
| Lung transplantation | 4 (3.7) |
| Advanced care planning | |
| Discussed but no advance directive written | 47 (43.1) |
| Advanced care directive completed | 50 (45.9) |
| Goals of care documented during admissions | 59 (54.1) |
| Palliative care support | |
| Palliative care consultant or registrar review in ALDS clinic | 104 (95.4) |
| Community palliative care team support | 60 (55.0) |
| Causes of death (n = 81) | |
| Respiratory cause | 68 (84.0) |
| Non‐respiratory causes | 7 (8.6) |
| Not stated | 6 (7.4) |
| Places of death (n = 81) | |
| Hospital palliative care unit | 27 (33.3) |
| Hospital acute bed | 18 (22.2) |
| Nursing home | 13 (16.0) |
| Home | 10 (12.3) |
| Community palliative care unit/hospice | 8 (9.9) |
| Not stated | 5 (6.2) |
Data are reported as counts with frequencies.
†
Including (but not limited to): breathing exercises, postures to reduce dyspnoea, activity pacing, energy conservation, fan therapy to face and breathlessness management plans. ALDS, advanced lung disease service; ICS, inhaled corticosteroid; LABA, long‐acting beta agonist; LAMA, long‐acting muscarinic antagonist.